Physician profile
Candy Thorpe
NPI 1376080291
$3,516.65
in general payments reported to CMS, 2019-2025
23 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $111 · 2023: $550 · 2024: $1,663 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,405.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,070.30 | 2022-2025 | |
| Janssen Biotech, INC. | $577.62 | 2023-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.82 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Gilead Sciences, INC. | $216.70 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $204.17 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $196.35 | 2024-2025 | Ibsrela |
| Pfizer INC. | $106.34 | 2023-2025 | |
| Lilly USA, LLC | $87.52 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $85.91 | 2023-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $80.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $68.86 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $53.19 | 2024 | |
| Genzyme Corporation | $43.61 | 2025 | |
| Celgene Corporation | $43.20 | 2024 | Zeposia |
| Evoke Pharma, INC. | $36.41 | 2023-2025 | Gimoti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $36.20 | 2024 | Idacio |
| Medtronic, INC. | $33.97 | 2024 | Interstim |
| Organon LLC | $31.69 | 2023-2024 | Renflexis, Hadlima |
| Takeda Pharmaceuticals U.S.A., INC. | $29.30 | 2024 | Entyvio |
| Ipsen Biopharmaceuticals, INC | $23.79 | 2025 | Iqirvo |
| Azurity Pharmaceuticals, INC. | $20.72 | 2025 | Suflave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.13 | 2024 | |
| Nestle Healthcare Nutrition INC. | $17.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candy Thorpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.